MediumEndocrinologyType 2 diabetes with cardiovascular diseaseca-mccqe1ca-rcpsc-im
A 63-year-old woman with a 10-year history of type 2 diabetes and a previous non-ST-elevation myocardial infarction is taking metformin at the maximally tolerated dose. Her HbA1c is 8.2%. Her estimated glomerular filtration rate (eGFR) is 70 mL/min/1.73 m² and she has no history of ketoacidosis. According to Diabetes Canada's pharmacologic guidelines, which additional agent is most appropriate to reduce cardiovascular risk and improve glycaemic control?